Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bausch Health Companies Inc. Common Stock (NY:BHC)

6.280 -0.340 (-5.14%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Carl Icahn's Biggest Bet Just Torched Half His Fortune ↗
Carl Icahn's empire, IEP, has collapsed 80% due to Hindenburg's short-selling attack. Icahn's net worth is down 75%. 
Via Benzinga
News headline image
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
Via ACCESS Newswire
News headline image
Bausch Health (BHC) Q3 2025 Earnings Transcript ↗
Bausch Health (BHC) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Bausch Health Companies's Earnings Outlook ↗
 
Via Benzinga
News headline image
Bausch Health Announces Third Quarter 2025 Results
Via ACCESS Newswire
News headline image
Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More ↗
Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 
Via Benzinga
News headline image
Bausch Health Announces Results of Special Meeting of Shareholders
Via ACCESS Newswire
News headline image
Insiders Signal Caution: A Deep Dive into Recent Trading Trends and Market Implications
Corporate insiders, often privy to the most granular details of their companies' health and future prospects, have been sending a clear signal to the market over the past 12-18 months: caution. A... 
Via MarketMinute
Topics Artificial Intelligence Economy Regulatory Compliance
News headline image
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
Via ACCESS Newswire
News headline image
Bausch Health to Announce Third Quarter 2025 Results on October 29
Via ACCESS Newswire
News headline image
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
Via ACCESS Newswire
News headline image
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Via ACCESS Newswire
News headline image
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System
Via ACCESS Newswire
News headline image
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
Via ACCESS Newswire
News headline image
A Look Into Bausch Health Companies Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Billionaire Investor Buys Google And This Gold Miner Stock ↗
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet. 
Via Benzinga
News headline image
Icahn Hedge Fund's Q2 Moves: Centuri Stake Soars, JetBlue Held, 2 Positions Exited ↗
Carl Icahn's 13F shows concentrated equity book, with top 10 holdings making up 98.76%. Notable changes in non-house names like CTRI and IFF. 
Via Benzinga
News headline image
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
Via ACCESS Newswire
News headline image
Bausch Health Announces Second Quarter 2025 Results
Via ACCESS Newswire
News headline image
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout ↗
Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials. 
Via Benzinga
News headline image
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
Via ACCESS Newswire
News headline image
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
Via ACCESS Newswire
News headline image
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
Via ACCESS Newswire
News headline image
Bausch Health Appoints New Chief Accounting Officer
Via ACCESS Newswire
News headline image
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.